Investigating a protein's role in breast cancer progression and treatment
Evaluation of HSPD1 (Heat Shock Protein, 60) as a theranostic target for breast cancer
This study is looking at a protein called HSPD1 to see how it affects the growth of aggressive breast cancer, and it hopes to find new ways to improve treatment and care for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tuskegee University NIH-funded |
| Lab location | 1 site (Tuskegee Institute, United States) |
| Project ID | NIH-10653869 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, HSPD1, is involved in the progression of breast cancer, particularly in its metastatic form. Using a novel technique, researchers have identified phage ligands that bind selectively to breast cancer cells that have undergone a transition associated with increased aggressiveness. The study aims to explore the relationship between HSPD1 expression and the severity of breast cancer, potentially leading to new imaging and therapeutic strategies that target this protein. Patients may benefit from insights that could improve treatment options and outcomes for breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with breast cancer, particularly those with metastatic disease.
Not a fit: Patients with non-cancerous conditions or those without breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies and diagnostic tools for breast cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting specific proteins for cancer treatment, suggesting potential success for this approach.
Where this research is happening
Tuskegee Institute, United States
- Tuskegee University — Tuskegee Institute, United States (Active)
Researchers
- Principal investigator: Bedi, Deepa — Tuskegee University
- Study coordinator: Bedi, Deepa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.